6 days Ago By ABMN Staff
Geode Capital Management LLC decreased its position in Akero Therapeutics, Inc. ( NASDAQ:AKRO – Free Report ) by 0.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission.
The fund owned 1,559,631 shares of the company’s stock after selling 11,381 shares during the quarter. Geode Capital Management LLC owned about 2.23% of Akero Therapeutics worth $43,399,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. AlphaQuest LLC raised its position in shares of Akero Therapeutics by 32,588.0% in the fourth quarter.
AlphaQuest LLC now owns 8,172 shares of the company’s stock valued at $227,000 after buying an additional 8,147 shares during the last quarter. Sei Investments Co. purchased a new stake in Akero Therapeutics in the 4th quarter worth approximately $303,000.
KLP Kapitalforvaltning AS acquired a new position in Akero Therapeutics in the 4th quarter valued at $306,000. XTX Topco Ltd purchased a new position in shares of Akero Therapeutics during the 3rd quarter worth $308,000. Finally, Proficio Capital Partners LLC acquired a new stake in shares of Akero Therapeutics during the fourth quarter worth $320,000.
Wall Street Analyst Weigh In AKRO has been the topic of several recent analyst reports. Canaccord Genuity Group increased their target price on Akero Therapeutics from $56.00 to $73.
00 and gave the stock a “buy” rating in a research report on Tuesday, January 28th. Morgan Stanley reissued an “overweight” rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. UBS Group upped their price target on shares of Akero Therapeutics from $42.
00 to $109.00 and gave the stock a “buy” rating in a research report on Friday, January 31st. Citigroup lifted their target price on Akero Therapeutics from $65.
00 to $80.00 and gave the company a “buy” rating in a report on Tuesday, January 28th. Finally, Bank of America raised shares of Akero Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the company from $35.
00 to $63.00 in a research report on Thursday, January 30th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, Akero Therapeutics presently has a consensus rating of “Buy” and an average target price of $76.
29. Akero Therapeutics Stock Up 5.4 % NASDAQ AKRO opened at $37.
60 on Tuesday. The stock has a market cap of $2.99 billion, a PE ratio of -10.
03 and a beta of -0.18. The business has a 50 day moving average price of $44.
46 and a two-hundred day moving average price of $35.98. Akero Therapeutics, Inc.
has a fifty-two week low of $17.86 and a fifty-two week high of $58.40.
The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.
05. Akero Therapeutics ( NASDAQ:AKRO – Get Free Report ) last released its quarterly earnings results on Friday, February 28th. The company reported ($0.
99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.01).
As a group, sell-side analysts predict that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.
Insider Transactions at Akero Therapeutics In related news, CFO William Richard White sold 676 shares of Akero Therapeutics stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $44.88, for a total value of $30,338.
88. Following the completion of the sale, the chief financial officer now owns 61,959 shares in the company, valued at approximately $2,780,719.92.
The trade was a 1.08 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link .
Also, insider Timothy Rolph sold 31,250 shares of the stock in a transaction on Monday, January 27th. The shares were sold at an average price of $55.77, for a total transaction of $1,742,812.
50. Following the transaction, the insider now owns 170,237 shares in the company, valued at $9,494,117.49.
This trade represents a 15.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here .
Over the last ninety days, insiders have acquired 341,309 shares of company stock valued at $15,863,578 and have sold 278,385 shares valued at $13,345,929. Corporate insiders own 7.94% of the company’s stock.
About Akero Therapeutics ( Free Report ) Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. Featured Articles Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
